Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof of concept study to investigate safety, tolerability, pharmacokinetics and the impact on pulmonary and systemic hemodynamics of a single oral dose of BAY 60 4552 in patients with biventricular chronic heart failure and pulmonary hypertension in a non-randomized, non-blinded, dose escalation design.

Trial Profile

Proof of concept study to investigate safety, tolerability, pharmacokinetics and the impact on pulmonary and systemic hemodynamics of a single oral dose of BAY 60 4552 in patients with biventricular chronic heart failure and pulmonary hypertension in a non-randomized, non-blinded, dose escalation design.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs BAY 604552 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Acronyms DOLAAR
  • Sponsors Bayer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top